Helena Ortega-Marzo

Wy
Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 243 publications

Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis.

Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis.

Journal: EULAR rheumatology open

Published: August 01, 2026

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Journal: Current opinion in rheumatology

Published: June 12, 2026

Two patterns of sacroiliac joint bone marrow oedema are apparent in AxSpA determined by HLA-B27 status, body mass index or psoriasis.

Two patterns of sacroiliac joint bone marrow oedema are apparent in AxSpA determined by HLA-B27 status, body mass index or psoriasis.

Journal: Joint bone spine

Published: March 28, 2026

Two Patterns of Sacroiliac Joint Bone Marrow Oedema are apparent in AxSpA Determined by HLA-B27 Status, Body Mass Index or Psoriasis.

Two Patterns of Sacroiliac Joint Bone Marrow Oedema are apparent in AxSpA Determined by HLA-B27 Status, Body Mass Index or Psoriasis.

Journal: Joint bone spine

Published: March 28, 2026

Better communication between rheumatologists and radiologists is key to improving MRI requesting and reporting data in axial spondyloarthritis: audit data from a single specialist centre.

Better communication between rheumatologists and radiologists is key to improving MRI requesting and reporting data in axial spondyloarthritis: audit data from a single specialist centre.

Journal: Rheumatology advances in practice

Published: February 23, 2026

Giving axial psoriatic arthritis the attention it deserves: Comment on: "Interspinous ligamentitis in patients with psoriatic arthritis".

Giving axial psoriatic arthritis the attention it deserves: Comment on: "Interspinous ligamentitis in patients with psoriatic arthritis".

Journal: Rheumatology (Oxford, England)

Published: February 19, 2026

Comment on: Interspinous ligamentitis in patients with psoriatic arthritis.

Comment on: Interspinous ligamentitis in patients with psoriatic arthritis.

Journal: Rheumatology (Oxford, England)

Published: February 18, 2026

Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition.

Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition.

Journal: Journal of autoimmunity

Published: February 11, 2026

Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial.

Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial.

Journal: The Lancet. Rheumatology

Published: February 03, 2026

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Journal: Current rheumatology reports

Published: January 28, 2026

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

Journal: RMD open

Published: January 26, 2026

Comment on: FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan: reply.

Comment on: FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan: reply.

Journal: Rheumatology (Oxford, England)

Published: January 19, 2026

Showing 1-12 of 243

Last Updated: 09/26/2026